INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–The first data from Europe, Israel and East Asia in the EMPRISE real-world evidence study have been presented, revealing a risk reduction…
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–The first data from Europe, Israel and East Asia in the EMPRISE real-world evidence study have been presented, revealing a risk reduction…